Pfizer

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Pfizer ducks out of Sangamo haemophilia A alliance

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

News

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

News

Pfizer elevates Chris Boshoff to top R&D role

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D

11 blockbuster drugs to look out for in 2025

Pfizer ducks out of Sangamo haemophilia A alliance

FDA approves flurry of drugs ahead of holiday season

ICER identifies new crop of 'unsupported' drug price rises

BridgeBio poised to challenge Pfizer after Attruby approval

Pfizer elevates Chris Boshoff to top R&D role

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks